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Abstract 
Objectives: Markov models, which characterise disease progression as specific health states 
based on clinical or biological measures. However, these measures are not always collected 
outside clinical trials. In this paper, an alternative approach is presented that uses real world 
data to define the health states and to model transitions between them, specific to a local setting 
to estimate the cost-effectiveness of telemonitoring (TM) versus no TM for heart failure.  
Methods: Incidence of hospitalisation for usual care was estimated from hospital episode 
statistics (HES) data in the UK and converted into a monthly transition matrix with five health 
states (four states are defined based on the number of hospitalisations in the previous year, and 
death) to estimate cost-effectiveness of TM in a local UK primary care trust (PCT) using 
probabilistic sensitivity analysis, from a health care perspective. 
Results: Geographical variation in hospitalisation rates were present, which led to different 
health state transition matrices in different localities. In the PCT that was evaluated, TM 
accrued mean additional costs of £3,610 and 0.075 additional quality adjusted life years 
(QALYs) compared to usual care per patient, resulting in a mean incremental cost effectiveness 
ratio of £48,172/QALY.  
Conclusions: The use of administrative data to define health states and transition matrices 
based on health service events is feasible, and TM was not cost-effective in our analysis. Given 
the increasing emphasis on using real world evidence, it is likely that these approaches will be 
used more in the future.   
Highlights 
 
 Markov models typically characterise disease progression using health states based on 
clinical or biological measures.  This paper presents an alternative way of 
characterising Markov models using administrative data (i.e. routinely available data) 
to define health states based on hospitalisations in the previous year. 
 Geographical variation in hospitalisation rates were present, which led to different 
health state transition matrices in different localities. The cost-effectiveness of 
telemonitoring for heart failure, based on locality specific administrative data, was 
estimated as £48,172/QALY.  
 This approach is shown to be capable of supporting locality-specific cost-
effectiveness analyses using real world data. 
 
Keywords 
Administrative data, Markov modelling, Cost-effectiveness, Routine data, Health Technology 
Assessment (HTA)  
Introduction 
Heart failure (HF) currently accounts for 1–2% of the annual healthcare budget in most 
developed countries and is associated with high levels of morbidity and mortality [1]. 
Telemonitoring (TM) can facilitate early detection of clinically significant changes as well as 
earlier intervention to re-stabilise the syndrome and prevent emergency admissions [2]. There 
have been studies of cost-effectiveness of TM compared to usual care for HF, estimated using 
modelling, to help decision makers assess value for money [3].  
A range of modelling techniques have been used [4], but cohort-based Markov models have 
been the most commonly used methods in health technology assessment (HTA) as they are 
relatively simple to develop, debug, analyse, and communicate [5]. Markov models are 
described in terms of the conditions that individuals can be in (“health states”), how they can 
move between such states (“transitions”), and how likely such moves are (“transition 
probabilities”) within a given time period (“cycle length”).  
Markov models can be specified in a number of different ways using different choices of state 
definitions, but biological or clinical measures (such as New York Heart Association [NYHA] 
classifications for HF) are frequently used. Also, simpler 2 health state models (death – alive) 
focusing on the number of (re)hospitalizations are often developed. However, measures like 
NYHA are not always collected outside clinical trials and number of (re)hospitalizations in 
clinical trials do not correspond to the real world hospitalization rate where there can be 
important local differences in case-mix, disease progression and clinical practice.  
The aim of this paper is to provide a proof of concept case study of using local administrative 
data to define health states and to model the transitions between them, specific to a given local 
setting. This is exemplified by the development a Markov model of HF that a) allows 
classification of HF patients into the different health states by the local decision makers and b) 
allows estimation of the transition probabilities from administrative data for their local setting. 
This approach facilitated the production of results that represent the cost-effectiveness of TM 
services at the local level, without the necessity of additional data collection. 
The next section describes the methods including the data sources and the modelling 
methodology. In the subsequent section, the results of a case study of TM for HF in a local 
primary care trust (PCT) are presented. In the discussion section, the key issues in modelling 
using routine data are highlighted along with recommendations for future researchers who are 




Based on the background work conducted to understand how researchers approached 
modelling HF previously and what information local decision makers would like to see in the 
modelling framework (see Appendix for more details), the measure of severity used needed to 
be related to available data on mortality and resource use, and identifiable in routine clinical 
practice of the local setting. As such, the number of hospitalisations in the previous year were 
used to define the states in the Markov model to allow easy classification of HF patients into 
the different states. This structure also includes an important deviation from the previous 
hospitalisation based models, namely, transitions are not uni-directional; patients can move to 
health states with lower numbers of hospitalisations. This was considered important by the 
stakeholders as it captures ‘stabilization’ of many patients following hospitalisation. The model 
used a monthly cycle length and life time horizon. 
Data analysis 
Data  
Hospitalisation data for HF patients in England were accessed from national Hospital Episodes 
Statistics (HES), which is a centralized dataset containing details of all admissions, outpatient 
appointments and accident and emergency (AE) attendances at NHS hospitals in England. Data 
were obtained for individuals who suffered at least one hospital admission for heart failure 
(ICD10 code I50) between March 2005 and March 2010. Mortality data were obtained from 
the Office for National Statistics with a pseudonymised identifier to allow linkage to HES data. 
In addition to hospital admissions, records for individuals’ AE attendances (which were further 
disaggregated into HF or OC attendances), GP attendances, and nurse visits were also 
extracted.   
Definition of health states 
The health states were based on the number of HF hospital admissions over the past year. Thus, 
state 0 described a population with no admissions to hospital for the condition over the past 
year; state 1 described a population with one HF admission in the past year; state 2 described 
a population with 2 HF admissions in the past year; and state 3 described a population who had 
been admitted 3 or more times for HF in the past year. Death is represented as state 4.  
Identifying individual patient histories 
HES data were used to reconstruct individuals’ history of hospital use and mortality, and to 
categorize them into health states at each point of time according to the number of admissions 
for HF in the preceding year (Figure 1)Figure . If an individual is admitted to hospital over the 
course of a year, their severity state will increase – that is, they transition up the chain of states. 
If they suffer no further admissions during a year they would be categorized as 0 – that is, 
transitions down the chain of states are also possible. Individuals leave the modelled population 
upon death. 
Figure 1 shows how the hospitalisation data are used to estimate the patient’s severity states 
over time. This (hypothetical) patient had hospital admissions at months 6, 20, 23, 25 and 27 
respectively. Up until 6 months, the patient is allocated to state ‘0’ i.e. no hospitalisations in 
the previous year. After 6 months, the patient is in severity state ‘1’ (i.e. one hospitalisation in 
the previous year) and remains in that state until after 18 months, where the patient goes back 
to state ‘0’ as it has been more than 12 months since their last hospitalisation. The patient stays 
in state ‘0’ until month 20, after which they go to state ‘1’. The patient then moves on to state 
‘2’ after month 23 as they had two hospitalisations in the previous year. And, then to state ‘3’ 
after month 25 as they had three hospitalisations in the previous year. A further hospitalisation 
in month 27 means they had four hospitalisations in the previous year so the patient is still in 
state ‘3’. 
Figure 1: Derivation of health states from hospitalisation data for a hypothetical patient 
Cohort data 
Individual patient data were then combined as cohort data, with the cohort at any time point 
being defined into different health states as described above. The number of admissions (HF & 
OC), emergency department attendances (HF & OC), and deaths that occurred in a given 
severity state were also calculated. Figure 2 shows the data derived from four PCTs accessed 
through a query run on HES data. The population in each PCT is categorised into states and 
the number of admissions, emergency department attendances (HF & OC) and deaths that 
occurred among individuals of a given severity state are presented.  
Figure 2: Data from four sample localities in UK by severity state 
This figure highlights two key constructs: a) defining disease severity using administrative data 
and b) need for modelling a given local setting. The frequency of all the outcomes increase 
with severity state, highlighting the relevance of classification of the severity states based on 
hospitalisations in the previous year. The figure also shows the variation of hospitalisation, 
mortality and resource use between the different PCTs, highlighting the need for local models.  
Estimating the transition probabilities 
Monthly Markov transition matrices were computed using a multi-step process. The hospital 
admissions data were analysed first to derive estimates of the rates, from which monthly 
probabilities of transition between states were calculated. The intervention effects (specified in 
terms of hazard ratios) were applied to the baseline event rates, to estimate the transition 
matrices for the TM patients. The R code together with hypothetical data can be found in the 
technical appendix and the reader can follow the steps in the code to operationalising this 
method, which is described in detail in subsections below. 
Calculating the rates 
Information on individual patient histories was aggregated to derive dynamics through time. 
The total number, 𝑛𝑎𝜀, of events of type 𝜀 occurring to individuals in a state 𝑎, and the total 
person-time spent in this state, 𝑇𝑎 was counted. The ratio of the count and the total person-time 
gives an estimate of the rate (hazard), 𝑟𝑎𝜀, at which event 𝜀 occurs to those in state 𝑎: 
𝑟𝑎𝜀 = 𝑛𝑎𝜀𝑇𝑎  
Estimating the transition matrix for usual care 
The transitions between states were treated as a continuous-time Markov process and writing 𝜀 = 𝑏 for the event transition to state 𝑏, and with the convention that 𝑟𝑎𝑏 = 0 when 𝑎 = 𝑏, the 
master equations (Kolmogorov forward equations) determining the probability, 𝑃𝑎(𝑡), of 
occupying state 𝑎 at time 𝑡 can be stated as follows 
𝑑𝑃𝑎𝑑𝑡 =  ∑(𝑟𝑏𝑎𝑃𝑏 − 𝑟𝑎𝑏𝑃𝑎).4𝑏=0  
Since the 𝑟𝑎𝑏 are constant in time, the equation can be solved using the matrix exponential of 
the transition rate matrix, 𝑅 
𝑅𝑎𝑏 = 𝑟𝑎𝑏 − ∑ 𝑟𝑏𝑐𝛿𝑎𝑏4𝑐=0  
where 𝛿𝑎𝑏 is the Kronecker delta function (1 if 𝑎 = 𝑏 and 0 otherwise). This results in 
estimation of the probabilities as 
𝑃𝑎(𝑡) =  ∑(𝑒𝑅𝑡)𝑏𝑎𝑃𝑏(0)4𝑏=0  
Using this approach, the usual care Markov monthly transition matrix, M was computed 
numerically in a software package supporting matrix exponentiation as M = exp (𝑅). 
Uncertainty in these rates was included by modelling event counts as following Poisson 
distributions, using a cycle length of one month (i.e. 𝑅 is measured in units of events per person 
per month). 
Incorporating effectiveness of interventions using hazard ratios 
The effects of TM on reductions in hospitalisations and mortality are included by computing a 
new transition matrix for TM via exponentiation, using new transition rates 𝑟′𝑎𝑏. The hazard 
ratio for hospitalisation, 𝐻𝑅ℎ𝑜𝑠𝑝, was applied to the upward state transitions relating to 
hospitalisation, i.e. states with 𝑎 ∈ {0,1,2,3} and 𝑎 < 𝑏: 
𝑟′𝑎𝑏 =  𝐻𝑅ℎ𝑜𝑠𝑝 . 𝑟𝑎𝑏 
The hazard ratio for death, 𝐻𝑅𝑚𝑜𝑟𝑡, was applied to transitions to the dead state (i.e. state 4): 
𝑟′𝑎4 =  𝐻𝑅𝑚𝑜𝑟𝑡 . 𝑟𝑎4 
As such, this captures both the instantaneous direct reduction in mortality rates in each state 
due to TM, and also the indirect reductions in mortality over time due to slowed progression 
towards more severe disease. The transition matrices for the TM arm are estimated in the same 
manner (as for the usual care arm) using matrix exponentiation described in the sub-section 
earlier.  
Evaluation scenario  
The methodology outlined above was used to develop a Markov model to compare TM with 
usual care for a cohort of 2,825 HF patients representative of the case-mix for an anonymous 
local PCT (named PCT1). The model used a monthly time cycle, a life time horizon (i.e. 
patients are followed until death) and National Health Service (NHS) health care perspective. 
Utilities and costs for each health state were based on published sources and primary data 
(described in more detail in Appendix). Costs and quality adjusted life years (QALYs) were 
discounted at a rate of 3.5%, in line with the NICE methods guide [9]. 
Results 
Estimating the transition rates 
Using the set of reconstructed individual histories for PCT1, the transition rates are estimated 
using the methods described in section 2 (Calculating the rates). The transition rates estimated 
for PCT1 are provided in Table A1 in the appendix. Within PCT1, it can be seen that not all 
patients transition from their current state to a state with a higher number of hospitalisations, 
which lends support to our choice of model structure. The number of admissions and 
emergency department attendances that occurred among individuals of a given severity state 
for PCT1 are shown in Table A1 in the appendix. It can be seen that the rate of events increases 
with severity state, suggesting that the health states capture disease progression. 
Estimating the transition matrix for usual care  
Given the transition rates, the transition matrix M was estimated numerically in R software 
package using methods described in section 2 (Estimating the transition probabilities). The 
transition matrix for PCT1 is provided in Table 1 below. Uncertainty was included by 
modelling event counts as following Poisson distributions i.e. we assumed 𝑛𝑎𝜀~𝑃𝑜(𝑟𝑎𝜀 . 𝑇𝑎), 
sampled new counts and re-computed rates as 𝑟𝑎𝜀 = 𝑛𝑎𝜀𝑇𝑎 .  
Incorporating effectiveness of telemonitoring 
The effect of TM on disease progression (i.e. progression through our severity states based on 
hospital admission frequency) and mortality was informed based on data from a meta-analysis 
by Pandor et al [10]. This estimated that medical support during office hours had the following 
hazard ratios: all-cause mortality of 0.76 [CrI: 0.49-1.18], and hospitalisation of 0.75 [CrI: 
0.49-1.1]. We modelled the uncertainty in these intervention effects with log-normal 
distributions with parameters chosen to match the mode and credible intervals: (𝜇, 𝜎) = (-0.274, 
0.170), (-0.288, 0.151), and (-0.051, 0.159), respectively.  
The hazard ratios for mortality and condition-specific hospitalisation were applied to the 
instantaneous rates of these events derived from the HES data. New transition matrices 
representing monthly progression between disease states for those on TM were then derived 
i.e. mortality, disease progression, and hospital admissions on TM were all estimated 
incorporating these hazard ratios. It should be noted that the hospitalisations occur at a lower 
rate on TM. However, it is assumed that emergency department attendances for a given severity 
state are independent of the treatment i.e. whether the cohort is on usual care or TM. 
Table 1. Monthly transition matrices for usual care and telemonitoring, and monthly 
rates for associated events   
Markov traces 
Figure 3 presents the evolution of the patient cohort of PCT1 (n=2825) through time, on usual 
care and with TM. The model predicts that over the course of five years, the HF patients on 
TM have a better prognosis compared to those not on TM.  
Figure 3: Case-mix through time with for usual care and telemonitoring. 
Cost effectiveness analyses 
Costs and QALYs can be estimated by using the information on the number of people in each 
state over the time horizon (i.e. Markov trace) with costs and utilities of each given state. 
Appendix 1 presents further details of the case study; the data on costs and utilities associated 
with each health state are used to estimate the overall costs and QALYs. TM accrued mean 
additional costs of £3,610 and 0.075 additional quality adjusted life years (QALYs) compared 
to usual care, resulting in a mean incremental cost effectiveness ratio of £48,172/QALY.  
Table 2 presents the costs, consequences and QALY results for 1 year and 5-year time horizon. 
The cost elements include the A&E and hospital admissions (reported separately for HF and 
other causes), costs for GP attendances, nurse visits and TM. This allows the decision makers 
to see where the costs are accrued and where there are potential cost savings. Cost-effectiveness 
results in the form of an incremental cost-effectiveness ratio (ICER) of TM compared to usual 
care are also presented. Scatterplot of costs and QALYs estimated from the probabilistic 
sensitivity analyses are presented in the appendix (see Figure A1), which suggest that the ICER 
is higher than the threshold of £20,000 per QALY. The cost-effectiveness acceptability curve 
(see Figure A2) shows that TM is the most cost-effective option at thresholds greater than 
£50,000 per QALY.  
Table 2: Costs, Consequences and QALY results for 1 year and life-time horizon  
Discussion 
In this paper, we presented an approach that uses routine hospitalisation data to define the states 
in a Markov model and estimate the transition probabilities for heart failure patients specific to 
a given local setting.  The novel aspect of this approach is the derivation of the transition matrix 
from administrative data, which requires categorization of the cohort into disease severity states 
and calculate event rates by severity. Our method was then used to assess the cost-effectiveness 
of TM, by including the evidence on TM intervention’s effectiveness in the form of hazard 
ratios concerning multiple, competing events (i.e. disease progression and mortality) 
incorporated into our Markov model.   
In the PCT that we evaluated, TM had a mean ICER of £48,172/QALY compared to usual care, 
suggesting that it is not cost-effective at the threshold of £20,000 per QALY. These analyses 
can be also performed at other local settings to capture local differences in case-mix, 
progression and resource use as long as the required data is available on a reasonable number 
of patients. Many organisations do have administrative datasets or electronic medical records 
(EMR) that utilise the ICD10 classifications, upon which our analyses are based, and these 
should be able to adapt the code and methods to their context. The administrative data needs to 
cover all hospitalisations and outpatient contacts related to the patient cohort.  This will be 
difficult to achieve if patient data are not routinely linked i.e. this type of analyses is not 
possible for settings that lack this kind of data. 
Our framework allowed for the inclusion of uncertainty based on the observed event counts 
and person-time in each locality. In combination, these features enabled us to generate locality-
specific projections of costs, consequences, QALYs, and cost-effectiveness analyses for 
regionally specified decision problems. This functionality was made freely available as a web 
model [11], where the users could log in, select a locality  in the UK and perform the analyses 
for that setting. 
However, there are some limitations to the approach used in this paper. Firstly, administrative 
data needs to be available in order to implement the approach used in this paper. These data 
may not always be available (e.g., in low resource settings) or forthcoming (e.g. if there are 
confidentiality issues), in which case this approach cannot be implemented. Also, as 
highlighted above, the hospitalisation-based Markov modelling approach applies best to 
chronic diseases where hospitalisation is a useful measure of both effectiveness and disease 
progression. Each HF hospitalisation is treated as the same in our analysis, independent of 
intensity or length of stay on the assumption that they average out at the population level. 
However, this may not be case for all situations and as such, it may not be sensible to use this 
approach for all conditions and interventions.  
The differences in event definitions and clinical practice may mean that measures of 
effectiveness based on service events (e.g. hospitalisations) are non-transferable between 
countries or providers.  This is less of a problem for physiological or functional health states 
(e.g. NYHA) which are more independent of clinical behaviours and health system 
characteristics. If this is the case, then models based on more robust health proxies will be 
required, together with compatible measures of effectiveness.  
In our case study, the treatment effect was estimated from published literature and assumed to 
be applicable to the usual care arm specific to the local setting. If the treatment effectiveness 
parameters also need to be estimated from routine data, issues of heterogeneity, lack of 
reporting or selection bias due to confounding need to be addressed. The randomised controlled 
trials (RCTs) do not have these same drawbacks associated with observational studies. 
However, there are methods such as propensity score matching, inverse probability weighting 
and instrumental variable methods to tackle issues associated with the use of observational data 
to inform estimates of treatment effectiveness [12,13].   
Populating a hospitalisation-based model with utilities (and costs) may be more difficult as the 
requisite data are typically reported by patient sub group defined in terms of physiological 
severity such as NYHA. The costs in the model presented in this paper have been estimated 
from the resource use associated with each health state (derived from HES data) and the unit 
costs associated with resource use (derived from published literature). However, the health-
related quality of life (HRQoL) values associated with each health state were not available in 
the HES data and thus, primary data needed to be collected. If such data on costs and HRQoL 
for the health states are not available from the routine data, the model needs to make 
assumptions about these parameters based on published literature and/or expert opinion. As 
with any modelling assumption, the validity of these model parameters needs to be checked 
with an expert group. 
However, this approach has many advantages over traditional Markov models that characterise 
disease progression by specific states based on clinical/biological measures. Whilst these 
clinical/biological measures are collected in randomised controlled trials, they are not always 
collected in the routine clinical practice.  As a result, models based on clinical/biological 
measures are limited in their applicability to several decision-making contexts. In particular, 
these approaches are not suited for estimating cost effectiveness in settings (e.g. local 
areas/hospitals) where access to detailed, locally specific information on clinical/biological 
measures is not routinely available. Using routine data to populate the Markov models such as 
the hospitalisation-based model presented in this paper overcomes this limitation and allows 
the users to perform analyses specific to a local setting.  
Whilst we have applied the approach to hospitalisation data relating to HF, this approach may 
also be suitable to be used for other conditions. The main requirements for the measures used 
to define health states (e.g. by hospitalisation count) are: a) that counts of this event strongly 
correlate with costs and or outcomes, and adequately capture disease progression; b) that the 
effectiveness of the intervention can be summarised as a hazard ratio applied to these rates. 
Based on our work we have identified the seven key steps in the use of administrative data to 
generate Markov models, which are summarised in Table 3. 
Table 3: Recommendations for analysing administrative data to generate Markov models  
This use of routine hospitalisation data for populating Markov models can also be generalised 
to other types of routine data and other modelling techniques. The dataset can be chosen based 
on type of disease under consideration - for example, registry data can be used to develop breast 
cancer Markov models [14]. The models need not always be Markov models and the technique 
that best suits the decision problem can be chosen – for example, statistical techniques such as 
multi state modelling [15, 16] can be used to incorporate the effect of key risk factors (such as 
age, gender, comorbidities, etc) or discrete event simulation [17] can be used for modelling 
based on time to event data from claims databases. These approaches, given they are dependent 
on routinely available data, allow the consideration of regional variation in the disease 
progression [18]. 
This work has identified several advantages and disadvantages associated with the use of 
administrative data to structure and populate health economic models, and future research 
should seek to validate such models against more conventionally structured models.  Key issues 
to consider would be the applicability of the approach to other conditions, and the role that 
regional variation plays in disease progression and cost-effectiveness.  
Conclusions  
This paper demonstrates the feasibility of using administrative data to define health states and 
transition matrices based on health service events. In the PCT that we evaluated, TM accrued 
mean additional costs of £3,610 and 0.075 additional quality adjusted life years (QALYs) 
compared to usual care per patient, resulting in a mean incremental cost effectiveness ratio of 
£48,172/QALY, suggesting that it is not cost-effective at the threshold of £20,000 per QALY. 
This approach has many advantages over conventional Markov modelling approaches, 
especially in chronic disease areas where hospitalisation is a useful measure of both 
effectiveness and disease progression. Given the increasing emphasis on using real world 
evidence, it is likely that these approaches can prove a valuable addition to traditional 
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Table 1. Monthly transition matrix for usual care and telemonitoring patients and 
monthly rates for associated events  
  Health state Events 
Usual 
Care 













0 0.981 0.004 0.000 0.000 0.015 0.007 0.036 0.004 0.055 
1 0.068 0.872 0.017 0.000 0.043 0.016 0.062 0.020 0.124 
2 0.004 0.094 0.777 0.041 0.084 0.032 0.097 0.053 0.178 
3 0.000 0.006 0.095 0.777 0.122 0.055 0.098 0.085 0.274 
4 0.000 0.000 0.000 0.000 1.000 0.000 0.000 0.000 0.000 
TM 
 










0 0.986 0.003 0.000 0.000 0.011 0.005 0.036 0.003 0.055 
1 0.068 0.885 0.013 0.000 0.033 0.012 0.062 0.015 0.124 
2 0.004 0.096 0.804 0.032 0.065 0.024 0.097 0.040 0.178 
3 0.000 0.006 0.098 0.801 0.094 0.041 0.098 0.064 0.274 
4 0.000 0.000 0.000 0.000 1.000 0.000 0.000 0.000 0.000 
Key: ED_HF: Emergency department attendances for heart failure, ED_OC: Emergency 
department attendances for other causes, A_HF: Hospital admission for heart failure, 
APC_OC: Hospital admission for other causes, TM: Telemonitoring 
  




1-year time horizon 
HF A&E attendances 273  
(264 - 282) 
263  
(255 - 271) 
Other A&E attendances 1,139  
(277 - 1,302) 
1,211  
(1,184 - 1,236) 
HF hospitalisations 228  
(197 - 253) 
225  
(218 - 232) 
Other hospitalisations 1,571  
(1,394 - 1,726) 
1,998  
(1,959 - 2,038) 
GP attendances 7,382  
(1,534 - 8,535) 
17,601  
( 8,006 - 23,818) 
Nurse home visits 55,223 
(23,573 - 71,481) 
46,620  
(21,855 - 62,813) 
Life time horizon 
HF A&E attendances 466  
(443 - 490) 
426  
(410 - 440) 
Other A&E attendances 1,999  
(487 - 2,267) 
2,010  
(1,956 - 2,059) 
HF hospitalisations 360  
(309 - 400) 
338  
(325 - 350) 
Other hospitalisations 2,697  
(2,384 - 2,973) 
3,251  
(3,172 - 3,332) 
GP attendances 13,394  
(2,768 - 15,541) 
30,268  
(13,686 - 40,763) 
Nurse home visits 100,345  
(43,158 - 127,283) 
80,156  
(37,509 - 107,630) 
Costs 
 
Telemonitoring Usual Care 
1-year time horizon 
 
HF A&E attendance costs £39,628  
(£38,326 - £40,944) 
£38,164  
(£37,004 - £39,317) 
Other A&E attendance costs £165,123  
(£40,161 - £188,756) 
£175,569  
(£171,691 - £179,264) 
HF hospitalisation costs £381,999  
(£79,381 - £441,692) 
£910,833  
(£414,317 - £1,232,565) 
Other hospitalisation costs £643,835  
(£556,568 - £715,221) 
£636,688  
(£616,650 - £656,409) 
GP attendance costs £2,702,212  
(£2,397,726 - £2,968,452) 
£3,436,607  
(£3,370,273 - £3,506,090) 
Nurse home visit costs £2,360,768  
(£1,007,732 - £3,055,829) 
£1,993,021  
(£934,312 - £2,685,240) 
Telemonitoring costs £6,101,729  
(£5,955,135 - £6,246,069) 0 (0 - 0) 
Life time horizon 
 
HF A&E attendance costs £67,607  
(£64,205 - £71,110) 
£61,717  
(£59,466 - £63,872) 
Other A&E attendance costs £289,879  
(£70,634 - £328,778) 
£291,386  
(£283,656 - £298,545) 
HF hospitalisation costs £693,144  
(£143,265 - £804,271) 
£1,566,354  
(£708,241 - £2,109,494) 
Other hospitalisation costs £1,016,594  
(£874,140 - £1,129,641) 
£954,603  
(£918,178 - £988,052) 
GP attendance costs £4,638,483  
(£4,099,914 - £5,112,923) 
£5,591,644  
(£5,455,328 - £5,730,187) 
Nurse home visit costs £4,289,756  
(£1,844,992 - £5,441,343) 
£3,426,679  
(£1,603,529 - £4,601,171) 
Telemonitoring costs £11,096,584  
(£10,629,586 - £11,575,420) 0 (0 - 0) 
Cost effectiveness results 
QALYs 2,548  
(1,853 - 3,318) 
2,336  
(1,681 - 3,028) 
Costs £22,092,046  
(£19,375,262 - £23,727,195) 
£11,892,384  









Identify event that is related to effectiveness data, and which will 
form the basis of the Markov health states. 
Specify model 
structure 
Identify data variables relating to exposure to intervention, risk-
stratification and other covariates that are related to costs and utilities. 
Gather patient data Acquire individual patient linked data over a time period which 
captures medium-to-long term disease progression. 
Map individual 
patient histories 
Generate patient histories across time. 
Allocate patients 
to different states 
Identify health states base on event counts, considering number of 
patients within each health state, and difference in costs and utilities 
between states. 




Apply hazard ratios for the intervention to the hazard matrix. 
 
  
Appendix 1: Conceptual modelling 
Background work was conducted to understand how researchers approached modelling HF 
previously and what information local decision makers would like to see in the modelling 
framework. As such, a targeted literature search was conducted to understand the state of the 
art of modelling in HF and an elicitation task was performed to understand the modelling 
requirements from the stakeholders.  
Reviews of previous HF models  
A systematic literature review by Goehler et al [6], which described the different decision 
analytic modelling approaches used to estimate the cost effectiveness of health technologies 
for HF, identified 34 modelling studies with the majority of them Markov models (n=27) along 
with three discrete-event simulation models and four mathematical equation sets models. Of 
the Markov models, seven studies used the NYHA functional classification system to model 
disease progression, ten studies applied a two state Markov model consisting of an ‘alive’ and 
a ‘death’ state whilst six studies applied a Markov model comprising hospitalisation states and 
a death state. The remaining four studies used combinations of the above or alternative clinical 
classification systems. 
A more recent review by Di Tanna et al [7], evaluating cost-effectiveness models for 
pharmacologic interventions in adults with HF, also reported similar findings. They identified 
64 publications with the majority of them Markov models (n=28) and trial-based evaluations 
(n=22), along with six discrete-event simulation models, seven partitioned survival models and 
one decision-tree model. Of the Markov models, seven studies focused on a two-state Markov 
approach based around the “alive” and “dead” states, five studies used the NYHA functional 
classification system to model disease progression whilst seven studies applied a Markov 
model comprising hospitalisation states and a death state (with the rest modelling HF alongside 
other cardiovascular events). 
Most models identified in these reviews were two state models (i.e. ‘alive’ and ‘death’ states), 
but they do not provide enough granularity to model the progression in disease severity. As 
seen above, and highlighted in the original reviews, most of the other models depend on NYHA 
class or number of hospitalisations as a proxy for disease severity and progression. These 
hospitalisation models only allowed maintenance of the same health state or progression to a 
higher number of hospitalisations (with higher costs and lower utilities). 
Elicitation of model requirements 
In order to identify the requirements for the model, a formal qualitative elicitation exercise was 
also conducted. Twenty-nine participants from four National Health Service (NHS) Trusts and 
eight commercial companies involved with manufacturing or supporting TM devices in the UK 
took part in the semi-structured, face-to-face and telephone interviews. The key findings from 
these interviews clearly demonstrated that functional classification systems (such as NYHA) 
are rarely used in routine practice and a requirement for the model to be capable of using locally 
specific data was highlighted. In particular, the model parameters needed to capture differences 
in burden of disease, case mix, hospitalisation rates and mortality. 
Issues in choosing the model structure 
Given the need to model disease severity, the two state models (i.e. ‘alive’ and ‘death’ states) 
are excluded as they do not provide enough granularity on disease severity. As such, the choice 
of model structure came down to either using NYHA classes or hospitalisations. The pros and 
cons of these approaches are briefly described below. 
The NYHA classification system is a clinical assessment tool that rates, on a four-point scale, 
patients' heart failure according to the severity of their symptoms and can be used for measuring 
disease progression. NYHA classes are appealing from a modelling perspective as there are a 
number of studies that link the different NYHA classes to resource use and quality of life 
(QoL). However, it is suggested that the NYHA classification is subject to some limitations as 
there is no consistent method for assessing NYHA class [8].  More importantly, whilst NYHA 
classes are usually assessed in clinical trials, they are not so common in routine clinical practice 
i.e. the patients are not always assessed using NYHA. This makes the estimation of cost-
effectiveness of interventions in real clinical practice using NYHA based models difficult.  
Hospitalisations, on the other hand, can be easily captured from administrative datasets, 
making them more readily available to local decision makers. In chronic conditions such as 
HF, where multiple hospitalisations are common, this characterisation allows multiple health 
states to be defined by frequency of hospitalisations.  Furthermore, hospitalisations could be 
considered an objective measure, although caution needs to be taken to ensure that there is 
consistency in definition. For instance, HF-related hospitalisations should be separated from 
other cause (OC) hospitalisations i.e. hospitalisations due to other comorbidities.  
Appendix 2: Cost-effectiveness of telemonitoring compared to usual care in PCT1 
The methodology outlined in the manuscript was used to develop a Markov model to compare 
telemonitoring with usual care for a cohort of 2,825 HF patients representative of the case-mix 
for PCT 1. Using the set of reconstructed individual histories, the transition rates are estimated 
using the methods described in section 2 (Calculating the rates) as shown in Table A1 below. 
Table A1: Transition rates between health states and associated event rates  
  Health state Events 































































0.000 0.000 0.000 0.000 
Key: ED_HF: Emergency department attendances for heart failure, ED_OC: Emergency 
department attendances for other causes, A_HF: Hospital admission for heart failure, A_OC: 
Hospital admission for other causes 
Given the transition rates, the transition matrices were estimated using methods described in 
section 2 (Estimating the transition probabilities). The transition matrices (presented in Table 
2) are used to estimate the number of people in each state over the whole time horizon (i.e. 
Markov trace presented in Figure 3), and the costs and utilities can be attributed to each given 
state to estimate the overall costs and QALYs.  
The next sub-section describes the costs and quality of life data used. Then, the costs and 
QALYs estimated for usual care (UC) and telemonitoring (TM) are presented before presenting 
the cost-effectiveness results in the form of an incremental cost-effectiveness ratio (ICER) of 
TM compared to usual care UC (see Table A1). The scatterplot of the costs and QALYs based 
on the probabilistic sensitivity analysis results are presented in Figure A1. 
Costs and Utilities 
Cost data was sourced from the HTA report by Pandor et al [9], and inflated to current 2018 
values using the health services index reported by Personal Social Services Research Unit. We 
used the following unit costs: £145 for an A&E visit (regardless of cause); £2,826 for a 
hospitalisation for HF; and £1,720 for a hospitalisation due to another cause and the cost of 
TM was £200 per month.   
Quality of life was modelled by health state, based on EQ5D scores elicited from HF patients 
in the participating NHS sites in the broader research project [10]. Participants were recruited 
via a postal survey between mid July 2013 and September 2013. The patient survey was sent 
to 713 patients in 6 community services in England; there were 261 responses.  Patients were 
being treated in the community for chronic diseases, with these primarily being heart and/or 
respiratory conditions.  In addition to the EQ-5D, the questionnaire asked about their use of 
telehealth and wider health services.  This information was then used to classify patients into 
each of the model's health states (in terms of frequency of hospitalisation in the last year) and 
generate a mean EQ-5D score.  Missing data meant that EQ-5D scores could be produced for 
254 patients.  The mean EQ-5D scores were 0.588, 0.523, 0.457, and 0.392, for the 0, 1, 2, and 
2+ health states, respectively. Quality of life as a function of health state was taken to follow a 
linear trend, with a variation in the intercept modelled as a normal fitted to the regression 
residuals. The intercept, slope and noise were (𝑎, 𝑏, 𝜎) = (0.589, −0.065,0.23). 
Given the EQ5D questionnaire is equally likely to be administered after a recent hospitalisation 
as it is to any time in over the past year (the time period used to define the model health states), 
the disutility of the hospitalisation is already included in the mean utilities estimated for each 
of the health states. As such a separate disutility during times of hospitalisation was not 
included the model. 
The inflow into the TM-eligible cohort was calculated from HES data that a mean of 64 new 
people per month were entering the cohort (i.e. experiencing a first hospital admission for HF). 
We compared a policy of permanent deployment of TM for all those with HF, vs no TM over 
a life-time horizon, with a discount rate of 3.5% per year.  
 
Cost-effectiveness results 
Scatterplot of costs and QALYs estimated from the probabilistic sensitivity analyses are 
presented in Figure A1, which suggest that the ICER is higher than the threshold of £20,000 
per QALY. The cost-effectiveness acceptability curve (see Figure A2) shows that TM is the 
most cost-effective option at thresholds greater than £50,000 per QALY.  
 
 
Figure A1: Cost-effectiveness plane for PCT1* 
* Red line indicates a cost-effectiveness threshold of £20,000 per QALY 
 
 
Figure A2: Cost-effectiveness acceptability curve for PCT1 
 
